FAAS
LGND icon

First Allied Advisory Services’s Ligand Pharmaceuticals LGND Stock Holding History

First Allied Advisory Services’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,470
Closed -$253K – 1137
2018
Q3 		$253K Buy
+1,470
New +$222K 0.01% 988

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return

First Allied Advisory Services's LGND Position: Q4 2018 in Review

First Allied Advisory Services sold out of Ligand Pharmaceuticals (LGND) in Q4 2018, closing a stake of 1,470 shares — an estimated $253K sold.

First Allied Advisory Services first reported a position in LGND in Q3 2018 and held it in 1 quarter. The position peaked at $253K in Q3 2018. 362 funds tracked by Wall St. Rank hold LGND as of Q4 2018.

  • First Allied Advisory Services reported no remaining Ligand Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • First Allied Advisory Services sold 1,470 Ligand Pharmaceuticals shares in Q4 2018, an estimated $253K.
  • First Allied Advisory Services first reported a position in Ligand Pharmaceuticals in Q3 2018 and held it in 1 quarter.
  • First Allied Advisory Services's Ligand Pharmaceuticals position peaked at $253K in Q3 2018.
  • 362 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2018.

Based on First Allied Advisory Services's 13F filing for Q4 2018, filed 15 Feb 2019.